Kurt Sheline
Partner @ Echo Health Ventures
Seattle, United States
Kurt Sheline is a Partner on the Strategic Investment Team at Echo Health Ventures, and is involved in all aspects of the investment and portfolio management process. Before joining Echo Health Ventures in 2017, Kurt was a Vice President in Cascadia Capital’s Healthcare Technology and Services group, based in Seattle, where he worked closely withmanagement teams in the life sciences, healthcare technology, and health care services industries, providing business development, positioning, sales & marketing, and transaction advisory and execution services.Kurt earned an MBA from the University of California, Berkeley, and a bachelor’s degree, magna cum laude, in Economics/Pre-Medical Studies from Claremont McKenna College. He lives with his wife, daughter, and Goldendoodle in Seattle, and enjoys golf, boating, craft beer, and a budding interest in mountaineering.
- Total investments:
- 6
- Last investment:
- Lead investor:
- 33%
Last updated:
For AI agents: llms.txt
Industries Kurt Sheline invests in
Stages Kurt Sheline invests in
Countries Kurt Sheline invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 4 (67%)
- Medical 1 (17%)
- Oncology 1 (17%)
- Biotechnology 1 (17%)
- Health Diagnostics 1 (17%)
Stage
- Series C 3 (50%)
- Series A 1 (17%)
- Series D 1 (17%)
- Venture - Series Unknown 1 (17%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| InStride Health provides evidence-based OCD and anxiety treatment to keep kids and teenagers engaged along the way. | $30M / Series C / Jun 15, 2026 | ||
| Optura is healthcare’s AI orchestration platform designed to turn disconnected pilots into a unified, enterprise-scale AI program. | $17.5M / Series A / May 14, 2026 | ||
| Thyme Care is a healthcare company that provides oncology care management services. The company offers a patient- and provider-integrated oncology solution, partnering with health plans to facilitate whole-person care for their members. Thyme Care seeks to revolutionize cancer care by providing personalized and holistic support to patients. Thecompany envisions a future where every cancer patient can access high-quality, individualized care that meets their unique needs and circumstances. | $55M / Series C / Jul 16, 2024 | ||
| Thyme Care is a healthcare company that provides oncology care management services. The company offers a patient- and provider-integrated oncology solution, partnering with health plans to facilitate whole-person care for their members. Thyme Care seeks to revolutionize cancer care by providing personalized and holistic support to patients. Thecompany envisions a future where every cancer patient can access high-quality, individualized care that meets their unique needs and circumstances. | Venture - Series Unknown / May 28, 2024 | ||
| At Scipher Medicine, we are committed to transforming the way providers prescribe drugs, as well as the way manufacturers, develop new drugs. We have built a molecular map of all protein interactions that identifies genomic signatures and links those to disease and predictive treatment outcomes. Using a simple blood sample to analyze RNA, we canpredict if a patient is likely to respond to a targeted therapy before therapy is prescribed. This insight allows patients to start the most effective therapy from day one. For our first commercial product, we have developed PrismRA®, a first-of-its-kind blood test that can predict which patients with rheumatoid arthritis are less likely to respond to TNFi therapies such as Humira® and Enbrel® so that such patients can go on alternative approved drugs.We also used a different one for the ACO Payer Summit, I’ve provided that as well: Scipher Medicine is building the future of patient treatment. Most patients who are prescribed blockbuster therapies today don't respond to treatment, costing the healthcare industry billions in wasted drugs while patients continue to suffer. Scipher's platform identifies which drug will work based on the patient's fundamental disease biology, and not based on symptoms, disease classification, or medical bias. A routine blood test predicts which drug he/she will respond to, with our first product focusing on rheumatoid arthritis, ensuring that the most optimal treatment is prescribed from day one. The molecular data generated by our tests is then used to fuel novel target discovery to address a clear unmet medical need in patients who do not respond to any existing therapy. | $110M / Series D / Feb 24, 2022 | ||
| At Scipher Medicine, we are committed to transforming the way providers prescribe drugs, as well as the way manufacturers, develop new drugs. We have built a molecular map of all protein interactions that identifies genomic signatures and links those to disease and predictive treatment outcomes. Using a simple blood sample to analyze RNA, we canpredict if a patient is likely to respond to a targeted therapy before therapy is prescribed. This insight allows patients to start the most effective therapy from day one. For our first commercial product, we have developed PrismRA®, a first-of-its-kind blood test that can predict which patients with rheumatoid arthritis are less likely to respond to TNFi therapies such as Humira® and Enbrel® so that such patients can go on alternative approved drugs.We also used a different one for the ACO Payer Summit, I’ve provided that as well: Scipher Medicine is building the future of patient treatment. Most patients who are prescribed blockbuster therapies today don't respond to treatment, costing the healthcare industry billions in wasted drugs while patients continue to suffer. Scipher's platform identifies which drug will work based on the patient's fundamental disease biology, and not based on symptoms, disease classification, or medical bias. A routine blood test predicts which drug he/she will respond to, with our first product focusing on rheumatoid arthritis, ensuring that the most optimal treatment is prescribed from day one. The molecular data generated by our tests is then used to fuel novel target discovery to address a clear unmet medical need in patients who do not respond to any existing therapy. | $82M / Series C / Mar 24, 2021 |
Co-Investors
About Echo Health Ventures
Echo Health Ventures is a venture capital firm that focuses on investing in health care companies. From offices in Durham, Portland, and Seattle, Echo Health Ventures invests in health care companies. They work with portfolio companies to accelerate their innovations to scale nationally. As stage-agnostic investors, they are committed to a newapproach to strategic investing – an approach that brings more than capital to the table, an approach focused on developing deep, high-value relationships with their portfolio companies.
Echo Health Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Dusty Lieb
Partner
|
|||
Karim Botros
Managing Partner
|
|||
|
Kurt Sheline
Partner
|
|||
Rob Coppedge
CEO & Founder
|
|||
Jessica Zeaske
Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Kurt Sheline invest in?
Kurt Sheline invests primarily in Health Care, Medical and Oncology startups, most often at Series C and Series A stage. Most of the 6 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Kurt Sheline?
Public channels for Kurt Sheline include LinkedIn, X (Twitter) and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Kurt Sheline last invest?
The most recent investment recorded for Kurt Sheline closed in Jun 2026. Shizune tracks 6 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
